Clinical Trials Directory

Trials / Unknown

UnknownNCT03778918

The Comparison Between the Biomarkers in Inflammatory Bowel Disease Patients and General Control Group

The Comparison Between That Expression Pattern and Disease Activity of Variable Biomarkers in Inflammatory Bowel Disease Patients and General Control Group. Multicenter, Prospective Study

Status
Unknown
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Bo-In Lee · Academic / Other
Sex
All
Age
19 Years – 75 Years
Healthy volunteers
Accepted

Summary

The aims of this study is to investigate a blood-based biomarker that can replace endoscopy in patients with inflammatory bowel disease. For this purpose, blood sample of patients wiht inflammatory bowel disease (ulcerative colitis, Crohn 's disease) was collected at the same time the endoscopy is performed, stored after centrifugation, and analyzed accordingly. Selected biomarkers from the blood sample were investigated to compare those of patients with inflammatory bowel disease and those of general controls. Males and females over the age of 19 participated in the study and are excluded if they have chronic kidney disease or blood clotting disease. The outcome is a find of a blood-based biomarker that best reflects a disease activity.

Detailed description

Inflammatory bowel disease refers to chronic inflammation of the unknown origin that occurs in the intestine. It usually refers to ulcerative colitis and Crohn's disease, which are idiopathic inflammatory bowel diseases. While it had been known to be a common disease in the western world, in recent decades the incidence of ulcerative colitis and Crohn's disease has rapidly increased in Korea as well. Endoscopic examination is a gold standard in order to determine the activity of inflammatory bowel disease, but it is hardly performed due to the cost and time of a test. Therefore, it is necessary to find a blood-based biomarker that replaces endoscopy. The objective of the study is to identify a new inflammatory marker that replaces endoscopy by comparing blood samples of patients with inflammatory bowel disease with those of general controls.

Conditions

Interventions

TypeNameDescription
OTHERinflammatory bowel diseaseblood based biomarkers in IBD such as REG3 alpha, serum calprotectin and hs-CRP
OTHERIBS or Normal Controlblood based biomarker compared normal control with IBD

Timeline

Start date
2016-08-01
Primary completion
2020-06-30
Completion
2020-12-30
First posted
2018-12-19
Last updated
2020-03-03

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT03778918. Inclusion in this directory is not an endorsement.